#EDIT

Last 24h 📈 Bullish 📈1

Last 7 Days 📈 Bullish 📈1

Last 30 Days 📈 Bullish 📈1

News 📈 Stocks

CRISPR Therapeutics Trades 48% Below Consensus as CASGEVY Revenue Climbs

September 23, 2026 (just now)

CRISPR Therapeutics remains a standout in the gene-editing sector as the only firm with an approved product, yet shares trade significantly below…

CRSP BEAM NTLA +3

🌍 AMERICAS Read More →